Dipeptidyl Peptidase 4 Inhibitor [EPC]

14832 reported adverse events

Drugs of this class: LINAGLIPTIN LINAGLIPTIN AND METFORMIN HYDROCHLORIDE EMPAGLIFLOZIN AND LINAGLIPTIN EMPAGLIFLOZIN, LINAGLIPTIN, METFORMIN HYDROCHLORIDE

These side effects are most commonly reported by patients taking drugs of the Dipeptidyl Peptidase 4 Inhibitor [EPC] class:

# Side effect Count
0 BLOOD GLUCOSE INCREASED 1018
1 NAUSEA 703
2 DIARRHOEA 653
3 ACUTE KIDNEY INJURY 619
4 FATIGUE 579
5 DRUG INEFFECTIVE 547
6 DIZZINESS 530
7 DYSPNOEA 526
8 VOMITING 446
9 OFF LABEL USE 433
See all common reactions for Dipeptidyl Peptidase 4 Inhibitor [EPC]

Drugs of the Dipeptidyl Peptidase 4 Inhibitor [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 CYSTOSTOMY 10 0.2128
1 5-HYDROXYINDOLACETIC ACID IN URINE INCREASED 12 0.2000
2 URETHRAL CARUNCLE 9 0.1765
3 PULMONARY VALVE DISEASE 18 0.1651
4 BLOOD MERCURY ABNORMAL 12 0.1519
5 PERICARDIAL DISEASE 20 0.0833
6 HEPATOJUGULAR REFLUX 12 0.0800
7 PERITONEAL HAEMATOMA 9 0.0720
8 GLYCOSYLATED HAEMOGLOBIN 9 0.0652
9 PHYSICAL EXAMINATION ABNORMAL 14 0.0622
See all enriched reactions for Dipeptidyl Peptidase 4 Inhibitor [EPC]